Kelly Lacob is a healthcare technologist, product designer, and systems thinker redefining how

we deliver care—making it more preventive, personalized, and accessible. Trained at Stanford

and Johns Hopkins in human biology, bioengineering, and business, Kelly has built her career

translating early-stage science into scalable products that change lives for traditionally

underserved patient populations.

Before co-founding Xella Health, Kelly led the product design and roadmap for the first

CRISPR-powered diagnostic platform at Mammoth Biosciences, and the development and

launch of the first FDA-cleared point-of-care and at-home PCR test at Visby Medical—a

diagnostic breakthrough that helped power early COVID-19 response efforts. Her portfolio of

past products spans more than a dozen healthcare innovations, including a remote-monitoring

platform for hypertension, diabetes, and preeclampsia, a surgical-supply bundling solution that

reduced postoperative infection, a community-based hearing-screening platform enabling

task-shifting to lower-level health workers, and a smart wound sensor and mobile app to prevent

pressure sores.

Now as Co-Founder and CEO of Xella Health, Kelly is applying her expertise in product design

and commercialization to bridge the gap between cutting-edge research and everyday clinical

care for women and their families.

Adriana Dantas is a global biotech and medical-device leader with more than 20 years of

experience bringing breakthrough technologies from bench to bedside. A biochemist and

pharmacist turned business strategist, she has built a career at the intersection of science,

operations, and commercialization—bridging research innovation with real-world impact.

Before co-founding Xella Health, Adriana held senior executive roles at Roche, Becton

Dickinson, and Mammoth Biosciences, where she led cross-functional teams spanning R&D,

operations, and go-to-market execution. Her leadership has guided product portfolios that

achieved first- and second-in-market share positions globally, and she has lived and led across

five countries, cultivating a truly international perspective on healthcare delivery and innovation.

One of her proudest achievements was leading the women's health division at Roche, including

the acquisition and multinational rollout of the Ariosa line for non-invasive prenatal testing.

She holds an MBA from FGV (Brazil) and Cranfield School of Management (UK), and a

Doctorate in Pharmacy and Biochemistry from the University of São Paulo.

Jesus Ching is a scientist, inventor, and entrepreneur with over 30 years of experience and

more than 50 patents spanning molecular diagnostics, genomics, proteomics, and

CRISPR-based technologies. A true pioneer in next-generation diagnostics, Jesus has built a

career transforming scientific innovation into clinically impactful, commercially successful

products.

He has founded multiple diagnostics companies, three of which were acquired by industry

leaders Bio-Rad, Luminex/DiaSorin, and Cepheid/Danaher. His deep technical

expertise—combined with a relentless focus on first-principles thinking—has led to the creation

and launch of numerous products across point-of-care, lab-based, and multi-omic testing

platforms that redefine what’s possible in human diagnostics.

At Xella Health, Jesus leads the company’s scientific and technological vision, applying his

decades of experience in molecular systems design to power Xella’s AI- and multi-omic-based

precision health platform for women. Jesus holds a PhD in Chemistry from Baylor University and

a BS in Biology and Chemistry from Houston Baptist University.

Taylor Hansen is an innovative brand and growth leader with 20 years of proven experience

building and scaling iconic global and emerging brands. She has led businesses across multiple

verticals within LVMH, VF Corporation, and Zadig&Voltaire, and most recently scaling her

award-winning consultancy, The Versed Group.

Blending creativity with commercial strategy, she drives growth that moves culture. At LVMH,

she concepted and led the build and commercial implementation of the world’s first AI-powered

skincare and color face finder—now a standard for leading wellness brands and responsible for

billions in conversion revenue.

A Sustainable MBA graduate and certified Integrative Health Practitioner, Taylor is deeply

committed to advancing women’s health innovation and Lyme disease awareness.

As Chief Marketing & Commercial Officer at Xella Health, Taylor joins the team in redefining the

future of women’s healthcare. A speaker, mentor, and Forbes contributor, she is known for

uniting brands and teams around purposes that are both socially responsible and commercially

powerful.

A pioneer in data science and computational biology, Olga Sazonova translates moonshot R&D

into market-moving products in consumer genomics, cancer detection, and personalized

nutrition.

During her Biomedical Engineering PhD at Boston University, Olga taught herself to code,

earning a coveted NIH postdoctoral fellowship in computational science at Stanford. Balancing

motherhood with her biotech career, she joined 23andMe, first leading massive genomic studies

in neurological disease before moving to the product team to build the core machine learning

models for their consumer polygenic risk scores. At GRAIL, she spearheaded the R&D for novel

AI-driven early cancer detection.

As Director of Data Science at Nutrisense, Olga built the research program from scratch,

directing IRB-approved clinical studies and unleashing LLMs to validate product efficacy. At

Xella Health, she now leads a team of scientists and engineers developing the first AI-driven,

multi-omics powered 'magnifying lens' to illuminate female reproductive health and biology.